.jpeg)
2026-05-12 03:08:03
Tucatinib, an oral TKI developed by Seagen, selectively targets HER2 to inhibit cancer cell growth. Approved by FDA in 2020 for advanced HER2+ breast cancer (including brain metastases) and expanded to RAS-wildtype HER2+ CRC in 2023. This treatment, combined with trastuzumab and capecitabine, significantly prolongs survival and improves outcomes. This article details indications, dosing, precautions, and safety profiles for informed clinical use.
2026-05-11 02:36:52
Pralsetinib, a highly selective RET inhibitor, is revolutionizing treatment for RET fusion-positive NSCLC and MTC. This article delves into its mechanism, clinical data, administration guidelines, and global accessibility, offering essential insights for patients and clinicians.
2026-04-30 04:14:23
This article details the mechanism of action, precise indications, eligible patient populations, and clinical value of elacestrant, analyzing its unique advantages and application boundaries in the treatment of endocrine-resistant hormone receptor-positive breast cancer.
2026-04-29 05:05:24
Selpercatinib is a highly selective RET kinase inhibitor indicated for the treatment of multiple advanced solid tumors associated with RET gene alterations, including non-small cell lung cancer, medullary thyroid cancer, and RET fusion-positive thyroid cancer. This guide provides detailed information on its indications, recommended dosage, dosage adjustments for special populations, important safety warnings, and drug interactions.
2026-04-28 04:44:27
This article provides a comprehensive overview of the approved indications, standard dosages for adults and children, administration methods, missed dose and vomiting management principles, as well as dose adjustments for special populations and adverse reaction management of the targeted drug entrectinib.
2026-04-28 04:28:10
This article provides a detailed analysis of the characteristics, mechanisms, high-risk factors, and clinical management points of bleeding risk associated with tepotinib in the treatment of MET-mutated non-small cell lung cancer, helping patients and healthcare professionals scientifically evaluate medication safety.
2026-04-28 04:21:32
This article systematically compares the mechanisms of action, clinical efficacy, side effect profiles, and applicable populations of lomustine and temozolomide, two alkylating antineoplastic agents, providing professional reference for treatment selection in patients with glioma and other tumors.
2026-04-28 03:25:11
This article provides a detailed analysis of the mechanisms of action and clinical therapeutic positioning of tepotinib and osimertinib, exploring the theoretical basis, research progress, and safety considerations of their combination therapy for patients with non-small cell lung cancer.
2026-04-28 03:18:38
This article provides a detailed analysis of the mechanism of action, tumor shrinkage logic, and efficacy evaluation methods of pazopanib, an anti-angiogenic targeted drug, to help patients with renal cell carcinoma and soft tissue sarcoma fully understand its therapeutic value.
2026-04-24 06:39:34
Tabrecta (Capmatinib) is an oral targeted drug designed for advanced non-small cell lung cancer (NSCLC) with METex14 skipping mutations. By inhibiting aberrant MET protein, it offers tumor shrinkage and prolonged response, alongside manageable side effects.
2026-04-23 05:36:07
Study reveals pazopanib’s potential in cutaneous angiosarcoma, offering improved survival and manageable safety despite not meeting PFS endpoint.
2026-04-22 07:26:16
As a bispecific T cell engager, Tarlatamab revolutionizes cancer treatment by activating immune attacks. This guide outlines unique immune-related adverse events (irAEs) and global management strategies.
